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Abstract
Background:  Hypoxia-inducible factor 1 alpha (HIF-1α) is involved in processes promoting
carcinogenesis of many tumors. However, its role in the development of colorectal cancer is unknown.
To investigate the significance of HIF-1α during colorectal carcinogenesis and progression we examined
its expression in precursor lesions constituting the conventional and serrated pathways, as well as in non-
metastatic and metastatic adenocarcinomas.
Methods: Immunohistochemistry and Western blot is used to analyse HIF-1α expression in normal
colonic mucosa, hyperplastic polyps (HPP), sessile serrated adenomas (SSA), low-grade (TA-LGD) and
high-grade (TA-HGD) traditional adenomas as well as in non-metastatic and metastatic colorectal
adenocarcinomas. Eight colorectal carcinoma cell lines are tested for their HIF-1α inducibility after
lipopolysaccharide (LPS) stimulation using western blot and immunocytochemistry.
Results: In normal mucosa, HPP and TA-LGD HIF-1α was not expressed. In contast, perinuclear protein
accumulation and nuclear expression of HIF-1α were shown in half of the examined SSA and TA-HGD. In
all investigated colorectal carcinomas a significant nuclear HIF-1α overexpression compared to the
premalignant lesions was observed but a significant correlation with the metastatic status was not found.
Nuclear HIF-1α expression was strongly accumulated in perinecrotic regions. In these cases HIF-1α
activation was seen in viable cohesive tumor epithelia surrounding necrosis and in dissociated tumor cells,
which subsequently die. Enhanced distribution of HIF-1α was also seen in periiflammatory regions. In
additional in vitro studies, treatment of diverse colorectal carcinoma cell lines with the potent pro-
inflammatory factor lipopolysaccharide (LPS) led to HIF-1α expression and nuclear translocation.
Conclusion: We conclude that HIF-1α expression occurs in early stages of colorectal carcinogenesis and
achieves a maximum in the invasive stage independent of the metastatic status. Perinecrotic activation of
HIF-1α in invasive tumors underlines a dual role of HIF-1α by regulating both pro-survival and pro-death
processes. HIF-1α up-regulation in response to LPS-mediated stimulation and periinflammatory
expression in invasive carcinomas suggest its involvement in inflammatory events. These patterns of HIF-
1α inducibility could contribute indirectly to the acquisition of a metastatic phenotype.
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Background
As a consequence of increased cellularity and prolifera-
tion, as well as enhanced metabolism within a tumor, the
oxygen concentration in solid neoplasms is generally
lower than in the adjacent non-neoplastic tissue [1,2]. In
fact, histopathological examination of carcinomas fre-
quently reveals hypoxic areas within the tumor mass,
mostly in the form of necrotic regions. As a reaction to
hypoxia tumor cells can alter their metabolism and acti-
vate survival mechanisms. Hypoxia inducible factor 1
(HIF-1) is a transcription complex that plays a crucial role
in coordinating the cellular response to oxygen stress con-
ditions [3]. As a result of hypoxic stress, HIF-1 activates
the transcription of a variety of genes regulating cell sur-
vival. HIF-1 is a heterodimer composed of one of the three
alpha subunits (HIF-1α, HIF-2α or HIF-3α) and one HIF-
1β subunit. Although HIF-1β is constitutively expressed,
hypoxia-mediated responses are determined by HIF-α
subunits. In normoxia, degradation of HIF-1α occurs.
Hypoxia leads to HIF-1α stabilization, resulting in a trans-
location of HIF-1α to the nucleus and binding to HIF-1β
forming the active HIF-1 complex. Activation of HIF-1α
has been reported in many solid tumors including carci-
nomas of the gastrointestinal tract [4-12]. However, the
role of HIF-1α in tumor progression of colorectal carcino-
mas is still unclear and the published data so far are con-
troversial. Thus, the expression of HIF-1α in some studies
was correlated with an increased tumor aggressiveness,
whereas in other studies a direct contribution to tumor
progression was not found.
HIF-1α is one of the key factors promoting carcinogenesis
independently of histogenetical origin. An enhanced
expression of HIF-1α from normal tissue through prema-
lignant lesions to carcinomas has already been observed
in prostate [13], gastric [14], breast [15], oral cavity [16],
cervical [17] and endometrial [18] carcinogenesis. So far,
detailed studies about the role of HIF-1α in the develop-
ment of colorectal cancer do not exist. In the case of color-
ectal carcinogenesis two major pathways with different
morphological features of the precursor lesions has been
described [19,20]. One is the convensional "adenoma-
carcinoma pathway" and the other is the alternative "ser-
rated pathway", in which serrated polyps replace the tra-
ditional adenoma as the precursor lesion. The incidence
of colorectal cancer did not differ significantly between
serrated and traditional adenoma.
In addition to hypoxia, more recent evidence suggests that
non-hypoxic pro-inflammatory stimuli, including
cytokines and growth factors, can also activate HIF-1α
under normoxic conditions and modulate the transcrip-
tion of hypoxia-associated genes [21]. This phenomenon
is well documented in inflammatory cells such as macro-
phages and monocytes [22-24] but similar observations
have also been made in tumor cell lines [25,26]. In this
context, the very potent pro-inflammatory bacterial
lipopolysaccharide (LPS) may be of particular importance
as a possible stimulator of HIF-1α in the gut under nor-
moxic conditions. Because LPS is a component of the cell
wall of gram-negative bacteria ubiquitously present in the
colon, normal and neoplastic intestinal cells are continu-
ously exposed to this factor [27]. Our previous studies
suggest that LPS could influence the progression of color-
ectal cancer through its receptor TLR4 (Toll-like receptor
4) [28] and the downstream transcription factor NFκB
(nuclear factor-κB) [29], leading to release of factors from
colon carcinoma cells capable of up-regulating endothe-
lial cell adhesion molecules [30]. Interestingly, a study
investigating gut ischemia, has found that LPS can induce
HIF-1α expression in enterocytes under normoxic condi-
tions [31]. However, a potential activation of HIF-1α in
colorectal carcinoma cells after exposure to LPS has not
been reported.
On the basis of the above considerations, in the present
study we set out to investigate the expression and role of
HIF-1α in colorectal cancer development and progres-
sion. To determine the potential role of HIF-1α in color-
ectal carcinogenesis we evaluated its expression in
classical and serrated premalignant lesions and in normal
mucosa. To examine whether HIF-1α can influence the
progressive behavior of colorectal carcinomas, we com-
pared its expression in non-metastatic and metastatic
malignant cases. Additionally, we verified its stimulation
in colorectal carcinomas under normoxic inflammatory
conditions by determining its inducibility after LPS stim-
ulation in various colorectal carcinoma cell lines.
Methods
Cell culture conditions and LPS stimulation experiments
The human colorectal carcinoma cell lines SW837,
HRT18, CX-1, CX-2, SW620, SW948, HT-29 and CaCo2
were grown in RPMI 1640 medium supplemented with
Glutamax (Sigma, St. Louis, MO, USA), 10% heat-deacti-
vated FCS (Gibco BRL, UK), 1% penicillin (Gibco) and
1% streptomycin (Gibco) at 37°C with 5% CO2. LPS
stimulation was performed by replacing the growth
medium of subconfluent cultures with medium supple-
mented with LPS derived from E. coli (Sigma), 1 μg/ml,
for 4 hours. After stimulation cells were harvested and
used for expression analysis.
Tissue samples
Colorectal polyp tissue were obtained from patients
undergoing colonoscopy with biopsy extraction at the
Klinikum Leverkusen during 2005–2007. In 20 of the
biopsy samples normal mucosa was also available for
observation. Colorectal carcinoma tissue samples were
obtained from 92 patients undergoing elective surgery atBMC Cancer 2008, 8:320 http://www.biomedcentral.com/1471-2407/8/320
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the University of Mainz during the years 1995–1999. The
investigation of these tissues was in accordance with the
rules of the responsible state ethical committee of the
Mainz University. All investigated tumors were T3 (subse-
rosal infiltration) and moderately differentiated (G2) ade-
nocarcinomas. This selection was performed with regard
to a potential relationship between the expression level of
HIF-1α and the metastatic status of the tumors. With
regard to the metastatic stage 38 cases were without tumor
metastasis to regional lymph nodes or distant organs (N0/
M0) during a follow-up period of at least 5 years after sur-
gery, 33 of the cases were characterized by haematogenous
(M+) and 21 by lymphogenous metastases (N+).
Western blotting
Protein extracts from harvested culture cells as well as nor-
mal and tumor epithelia derived from patients undergo-
ing surgical resection of colorectal cancer were used. From
each sample aliquots containing 20 μg of total protein
were separated on sodium dodecyl sulphate-polyacryla-
mide gels SDS-PA (10%) and then transferred to polyvi-
nylfluoride (PVDF) membranes (Immobilen-P, Millipore
Corp.) in accordance with standard procedures. Incuba-
tion with the primary antibodies to mouse monoclonal
anti-HIF-1α (1:100) (Stressgen, Victoria, BC Canada), and
rabbit polyclonal anti-β-actin (1:100) (Serva, Heidelberg,
Germany) was performed overnight by 4°C. Immunode-
tection was performed using the alkaline phosphatase
(AP) conjugated anti-mouse and anti-rabbit IgG (1:1000)
(Sigma).
Immunohistochemistry/cytochemistry
All immunohistochemical reactions were conducted
using formalin-fixed and paraffin-embedded samples.
After deparaffinization the samples were treated in a
microwave oven in EDTA buffer for 15 minutes. For
immunocytochemistry cytospins were prepared. Subse-
quently, fixation in an mixture of acetone and 4% forma-
lin was carried out. Incubation with the primary antibody
to HIF-1α (1:100) (Stressgen) and the secondary anti-
body, horse anti-mouse biotinylated IgG (1:200) (Vector,
Burlingame, CA, USA) was carried out in accordance with
standard protocols using the Vectastain Elite reagent (Vec-
tor). Sections were counterstained with Mayer's hematox-
ylin. To prove the specificity of the immunoreactions
every sample was stained solely with the secondary anti-
body. This immunoreaction was in every case completely
negative. The additionally required check of antibody
specifity by HIF-1α lacking cells is demonstrated in the
non-hypoxic, and non-inflammatory colonic mucosa
where none of the cells express HIF-1α.
Evaluation of HIF-1α staining
Immunostaining reactions of each sample were evaluated
by three authors independently (N.S., C.J., M.T.). Specific
immunoreactivity was observed in the cytoplasm and in
nuclei of the tumor cells. Since cytoplasmatic staining was
observed homogeneously in the tumor cells, the cases
were classified according to staining intensity in weakly,
moderately, and strongly positive. Nuclear immunoreac-
tivity was heterogeneous in the tumor, so that the score
was ascertained by consideration of both staining density
and intensity. The density of nuclear staining was classi-
fied as follows: 1, nuclear staining in less than 20% of
cells; 2, nuclear staining in 20–40% of cells; 3, nuclear
staining in more than 40% of cells. Nuclear staining inten-
sity was estimated as 1, weak and 2, strong. The multipli-
cation of these two values gave the final score for nuclear
staining: 1–2, weak; 3–4, moderate; 5–6, strong.
Statistical analysis
The association of staining intensity with tumor stage was
assessed with χ2 (Fisher's exact test). P < 0.05 was consid-
ered to be significant in all statistical analyses.
Results
HIF-1α expression in non-neoplastic and premalignant 
colorectal lesions
In the case of colorectal carcinogenesis two different path-
ways with distinct morphological features of the precursor
lesions has been described [18,19]. In the classical path-
way the precursor lesion is the traditional adenoma (TA),
with variable degrees of dysplasia, ranging from low grade
(TA-LGD) to high grade (TA-HGD). In the serrated path-
way the histopathological sequence begins with the
hyperplastic polyp (HP) without malignant potential, fol-
lowed by the sessile serrated adenoma (SSA), recognised
as a precursor lesion. A summary of the HIF-1α immunos-
taining profile in non-neoplastic tissue and in precursor
lesions of colorectal carcinogenesis is provided in Table 1.
Normal colonic mucosa, HP and TA-LGD showed neither
specific cytoplasmic nor nuclear HIF-1α expression (Fig-
ure 1A–C). In these samples the mucus content of the
colonic goblet cells leads to a non-specific immunoreac-
tivity. In contrast, SSA (7 of 13 samples) showed a strong,
diffusely perinuclear HIF-1α expression with nuclear
immunopositivity in about 10% of the cells (Figure 1D1,2
). Additionally, TA-HGD (10 of 20 samples) showed a
strong perinuclear, cytoplasmatic and focally nuclear pos-
itive immunostaining for HIF-1α. (Figure 1E1,2). In both
lesions, the intense immunoreactivity was observed on
the surface but not in the lower crypts. I
HIF-1α expression in non-metastatic and metastatic 
colorectal carcinomas
HIF-1α protein expression in neoplastic tissue, but not in
the adjacent normal mucosa was confirmed by western
blot analysis of each of two non-metastatic and metastatic
colorectal carcinomas (Figure 2).BMC Cancer 2008, 8:320 http://www.biomedcentral.com/1471-2407/8/320
Page 4 of 13
(page number not for citation purposes)
HIF-1α expression in precursor lesions of colorectal carcinogenesis Figure 1
HIF-1α expression in precursor lesions of colorectal carcinogenesis. In normal mucosa (A), HP (B) and TA-LGD (C) 
specific HIF-1α expression was not seen. SSA and TA-HGD showed a strong diffusely perinuclear (D1 and E1) and on the sur-
face crypts focally nuclear (D2 and E2) HIF-1α immunopositivity.BMC Cancer 2008, 8:320 http://www.biomedcentral.com/1471-2407/8/320
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Immunohistochemical expression of HIF-1α was
observed in the cytoplasm and in the nucleus of the tumor
cells in all investigated cases but with different staining
intensity (Figure 3). As shown in table 2 there was no sig-
nificant correlation in the cytoplasmatic or nuclear expres-
sion between non-metastatic tumors and carcinomas with
lymph node and distant metastases. Topological differ-
ences of immunoreactivity between the superficial tumor
fraction and the invasive tumor edge were not seen. The
cytosolic staining distribution in each specimen was
widely homogenous. In contrast, the distribution of the
number of positive tumor nuclei and the nuclear immu-
nostaining intensity of HIF-1α was heterogeneous but
without significant differences according to the metastatic
status (Table 2). However, the distribution of the active,
Table 1: HIF-1α expression in benign and premalignant 
colorectal lesions
n HIF-1 positivity
normal mucosa 20 0
HP 20 0
TA-LGD 20 0
TA-HGD 20 10 (50%)
SSA 13 7 (54%)
Abbreviations: HP – hyperplastic polyp, TA-LGD – tradtional 
adenoma-low grade dysplasia, TA-HGD – tradtional adenoma-high 
grade dysplasia, SSA – sessile serrated adenoma
Detection of HIF-1α in human non-metastatic (A) and metastatic (B) primary colorectal carcinomas by Western blot Figure 2
Detection of HIF-1α in human non-metastatic (A) and metastatic (B) primary colorectal carcinomas by West-
ern blot. Staining with anti-β-actin (bottom blots respectively) was performed as control for loading. (N: corresponding nor-
mal epithelium; T: tumor epithelium).BMC Cancer 2008, 8:320 http://www.biomedcentral.com/1471-2407/8/320
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Cytosolic (A-C) and nuclear (D and E) HIF-1α expression profiles detected in colorectal carcinomas Figure 3
Cytosolic (A-C) and nuclear (D and E) HIF-1α expression profiles detected in colorectal carcinomas. With 
respect to the cytoplasmic expression intensity weak (A), moderate (B) and strong (C) immunoreactivity was detected. With 
respect to the nuclear expression intensity weak (D) and strong (E) immunoreactivity was seen.BMC Cancer 2008, 8:320 http://www.biomedcentral.com/1471-2407/8/320
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endonuclear HIF-1α form in the tumor was not haphaz-
ard, but strongly associated with histological features such
as necrosis and severe peritumoral inflammation. 65 of
the 92 tumors examined were characterized by abundant
central necrosis in the atypical glands accompanied by
inceased HIF-1α immunoreactivity both in density and
intensity in the vicinity of these areas in 55 cases (85%)
(Figure 4A). In these samples nuclear HIF-1α expression
was detected in cohesive tumor epithelia surrounding
necrosis and in dissociated cells destined to undergo cell
death (Figure 4A1,2). 38 cases of the examined 92 tumors
showed a severe peritumoral inflammation, characterized
by dense confluent, mixed and mainly granulocyte-rich
inflammatory infiltrates. The inflammation was located in
the superficial tumor ulceration and along the infiltrative
pathway of the tumor. In 28 of these cases (74%) an
intensive nuclear HIF-1α expression of surrounding
tumor cells was observed (Figure 4B1,2 and 4C1,2).
Non-hypoxic HIF-1α stimulation by the pro-inflammatory 
signal, LPS, in colorectal carcinoma cell lines
Since a strong association between nuclear expression of
HIF-1α and severe peritumoral inflammation was
observed in situ, the question arises whether LPS stimula-
tion of colorectal carcinoma cell lines leads to up-regula-
tion of this transcriptional factor. In this context we
examined by Western blot HIF-1α expression in diverse
unstimulated and LPS-stimulated colorectal cell lines –
SW837, HRT18, CX-1, CX-2, SW620, SW948, HT-29 and
CaCo2. The LPS-stimulation experiments were conducted
under normoxia (21% O2). As shown in Figure 5 all eight
cell lines were negative for HIF-1α in the native condition.
Interestingly, LPS stimulation of these cell lines resulted in
HIF-1α up-regulation. Since the active form of HIF-1α is
located in the nucleus we next examined its subcellular
localization by immunocytochemistry (Figure 6). LPS-
treatment of the colorectal carcinoma cell lines was due to
enhanced perinuclear accumulation and nuclear translo-
cation of HIF-1α 4 hours after stimulation.
Discussion
The present study represents a systematic morphological
investigation of HIF-1α in colorectal cancer development.
So far, only one study reported detection of HIF-1α m-
RNA in four of nine investigated adenomas [7]. Our anal-
ysis demonstrated a significant induction of HIF-1α in
half of the cases of the premalignant lesions SSA and TA-
HGD. In contast, in normal mucosa, in benign HP and in
TA-LGD, which is known to have only a low risk of malig-
nant transformation HIF-1α expression was absent. Since
the investigated preneoplastic lesions did not show any
necrosis that expression is independent of hypoxia. Due
to the fact that in benign tissue HIF-1α is not detected, the
expression in tumor tissue could arise from genetic altera-
tions. In fact, HIF-1α is involved in tumor progression by
promoting genomic instability [32]. In the most common
traditional pathway of colorectal carcinogenesis the chro-
mosomal instability by stepwise mutation of Ki-ras, APC,
and p53 genes generally leads to development of approxi-
mately 70%–85% of colorectal carcinomas [33]. Whether
an interactive correlation exists between Ki-ras or APC and
HIF-1α activity status still remains to be determined.
However, induction of HIF-1 activity by loss-of-function
mutations of the tumor suppressor gene p53 has already
been observed [34]. Sugai et al reported about progressive
increase in mutations of the p53 gene in colorectal adeno-
mas from low-grade to high-grade [35]. In this context, we
suggest that this observation could be associated with our
observations of HIF-1α upregulation in the same stage of
colorectal carcinogenesis. The serrated pathway shown in
about 15% of the colorectal carcinomas demonstrates
BRAF  mutation and methylation/silence of the MLH-1
mismatch repair complex in the context of microsatellite
instability [34]. Interestingly, BRAF mutations are rare in
HP (2%) but very frequent in SSA (75%) [36-38]. Nota-
bly, a recent study with melanoma cells has shown for the
first time that BRAF mutation increases HIF-1α expression
[39]. MLH-1 methylation has been detected in 36% of HP
and in 70% of SSA [40,41]. MLH-1 gene was downregu-
lated in hypoxia but a direct involvement of HIF-1α has
not been found [42]. We conclude that overexpression of
HIF-1α can occur early in colorectal carcinogenesis in
both the traditional (adenoma-carcinoma seqence) and
serrated pathway. We suppose that this HIF-1α activation
is associated with the stepwise progressive genetic insta-
bility during colorectal cancer development. Further
Table 2: HIF-1α expression in non-metastatic (N0/M0), lymphogenously-metastatic (N+) and haematogenously-metastatic (M+) 
colorectal carcinomas
cytoplasmatic HIF-1α expression nuclear HIF-1α expression
metastatic status n weak mod strong weak mod strong
N0/M0 38 5 12 21 8 6 24
N+ 21 5 6 10 3 10 10
M+ 33 6 11 16 3 17 13
With respect to the T status all investigated tumors were T3 and moderately differentiated (G2). No statistical significance between cytoplasmtic or 
nuclear HIF-1α expression and the metastatic status was observed.BMC Cancer 2008, 8:320 http://www.biomedcentral.com/1471-2407/8/320
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Accumulation of nuclear HIF-1α in perinecrotic (A1,2) and periinflammatory (B1,2 and C1,2) regions of the tumor tissue Figure 4
Accumulation of nuclear HIF-1α in perinecrotic (A1,2) and periinflammatory (B1,2 and C1,2) regions of the 
tumor tissue. In perinecrotic areas HIF-1α activation was seen in cohesive tumor epithelia surrounding necrosis and in disso-
ciated, dying tumor cells. In periiflammatory areas tumoral HIF-1α activation was seen in the superficial tumor ulceration (B1,2) 
and in severe inflammation along the infiltrative pathway (C1,2). Magnification: 1 = 200×, 2 = 400×BMC Cancer 2008, 8:320 http://www.biomedcentral.com/1471-2407/8/320
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investigations are necessary to elucidate the precise mech-
anisms of this interaction.
In a previous in vitro study with the human colon carci-
noma cell line HCT-116 it was demonstrated that HIF-1α
regulates the expression of genes encoding proteins
involved in the pathophysiology of tumor invasion [43].
In our present in situ study, in comparison with the ade-
nomas in colorectal adenocarcinomas a conspicuous
increase in density and intensity of HIF-1α expression was
found, reflecting a gradual increase in expression level
throughout the sequence of intestinal carcinogenesis with
a maximum in the stage of the invasive phenotype. The
distinctly elevated HIF-1α expression in malignant tissue
allows the assumption of a relevant contribution of the
characteristic hypoxic microenvironment. In all investi-
gated cases a positive HIF-1α expression was seen with
cytosolic and nuclear localization, consistent with synthe-
sis in the cytoplasm and subsequent translocation to the
nuclei. Although the cytoplasmic staining distribution
was homogenous, nuclear staining distribution was not
uniform and showed an accumulated presence in the
vicinity of tumor necrosis and the neighborhood of severe
peritumoral inflammation. This topological pattern of the
transcriptionally active form provides evidence that HIF-
1α could play a crucial role in conditions characteristic of
tumoral microenvironment, such as necrosis and inflam-
mation, giving low levels of oxygen and high levels of
inflammatory cytokines. Interestingly, in the perinecrotic
regions nuclear positivity was seen in cohesive tumor epi-
thelia of the atypical glands surrounding areas of necrosis
but also in dissociated cells within necrosis. According to
our view, these histopathological findings underline the
dual, apparently paradoxical role of HIF-1α in regulating
both pro-survival and pro-death processes [44]. HIF-1α
activation in the cohesive tumor cells could be explained
as transduction to an adequate adaptative intracellular
response to prevent from cell death. Simultaneously, HIF-
1α activation in the dissociated tumor cells could be
explained as initiation of a "one way" cascade leading to
cell death.
Our study adds new data to support the concept of HIF-1α
involvement in normoxic inflammatory processes. HIF-
1α activation in colorectal cancer specimens was seen in
the vicinity of severe inflammation located in the superfi-
cial tumor ulceration and along the invasion pathway.
Due to the fact that intestinal mucosal injury may permit
Detection of HIF-1α in unstimulated and LPS-stimulated human colorectal carcinoma cell lines by Western blot Figure 5
Detection of HIF-1α in unstimulated and LPS-stimulated human colorectal carcinoma cell lines by Western 
blot. Staining with anti-β-actin was performed as control for loading.BMC Cancer 2008, 8:320 http://www.biomedcentral.com/1471-2407/8/320
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translocation of bacteria and endotoxin, this topological
accumulation of the active form of HIF-1α could be of
great importance for tumor progression [45]. Strong direct
evidence suggests that cancer-associated inflammation
promotes tumor growth and progression [46]. In the past,
we identified LPS, an endotoxin of ubiquitously existing
colonic bacteria, as a pivotal pro-inflammatory stimulus
increasing the aggressive behavior of colorectal carcino-
mas [28-30]. We report here that LPS stimulation of
diverse colorectal carcinoma cell lines induced HIF-1α
expression and translocation to the nucleus. These find-
ings demonstrate that LPS is a non-hypoxic stimulus for
HIF-1α in colorectal carcinomas. Based on our results we
hypothesize that HIF-1α could function as a linking tran-
scription factor for LPS-mediated processes along the
tumor invasion from the luminal site to the site of deepest
penetration.
In an in vitro study we recently reported that HIF-1α
upregulation in response to hypoxia was accompanied by
a significantly increased production of vascular endothe-
lial growth factor (VEGF) in two of five colorectal carci-
noma cell lines [47]. Kuwai et al reported an hypoxia-
induced increase of HIF-1α and VEGF in three of the four
examined colorectal carcinoma cell lines [6]. These
researchers and others described a strong association
between HIF-1α and VEGF expression in colorectal carci-
noma specimens [6,7,10]. Since VEGF promotes lym-
phangiogenesis and angiogenesis in the primary tumor,
thereby paving the way for metastasis, these findings sug-
gest that HIF-1α plays a determinative direct role in the
processs of colorectal cancer metastasis. However, in our
current in situ investigations there were no significant dif-
ferences in the HIF-1α expression levels between non-
metastatic tumors and carcinomas with lymph node and
distant metastasis. The published data so far concerning a
correlation between HIF-1α expression and metastatic
disease status of colorectal carcinomas are controversial.
In accordance with our results Joshimura et al [8] and
Wincewicz et al [12] found that HIF-1α expression did not
differ in relation to metastatic stage. In contrast, in two
other studies a significantly higher expression of HIF-1α
was observed in Dukes stages C or D, characterized by a
positive status for nodal or distant metastases [7,11]. Lu et
Positive cytoplasmic and nuclear expression of HIF-1α in LPS-stimulated SW620 (A2) and HRT-18 (B2) colon carcinoma cell  lines compared to native conditions (A1 and B1) Figure 6
Positive cytoplasmic and nuclear expression of HIF-1α in LPS-stimulated SW620 (A2) and HRT-18 (B2) colon 
carcinoma cell lines compared to native conditions (A1 and B1).BMC Cancer 2008, 8:320 http://www.biomedcentral.com/1471-2407/8/320
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al [10] showed that HIF-1α expression was strongly asso-
ciated with lymph node metastasis, whereas Kuwai et al
[6] report a significant correlation with liver but not with
lymph node metastasis. Because of the chosen design in
this study with comparison of non-metastatic and meta-
static colorectal carcinomas with the same grading of dif-
ferentiation and infiltrating depth, the influence of both
essential tumor features on the HIF-1α expression can be
excluded. In previous in vitro experiments we demon-
strated the relevance of tumor differentiation for HIF-1α
inducibility [47]. Well-differentiated colorectal carcinoma
cell lines were hypoxia-resistent, showing unchanged lev-
Schematic illustration of the HIF1α-mediated pathway in colorectal carcinogenesis and tumor progression Figure 7
Schematic illustration of the HIF1α-mediated pathway in colorectal carcinogenesis and tumor progression.BMC Cancer 2008, 8:320 http://www.biomedcentral.com/1471-2407/8/320
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els of HIF-1α and VEGF in response to reduced oxygen
stress conditions.
Conclusion
We conclude that HIF-1α expression occurs in early stages
in the classical and serrated pathway of colorectal carcino-
genesis and achieves a maximum in the invasive stage,
independent of the metastatic status of the primary tumor
(Figure 7). Since the acquisition of metastatic phenotype
is a multistep event, the HIF-1α associated perinecrotic
processes of both tumor cell survival and death and LPS-
mediated inflammatory response could indirectly con-
tribute to this endpoint.
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